MATCH-D Medication Appropriateness Tool for Comorbid Health conditions during Dementia

WACHA
  • Home page
  • Early Stage Dementia
  • Mid Stage Dementia
  • Late Stage Dementia
  • All Stages
    • Principles of medication use
    • Treatment Goals
    • Medication reviews
    • Preventative medications
    • Symptom Management
    • Medications to modify dementia progression
    • Psycho-active medications
  • About
  • Research
  • Downloads
You are here: Home / Late Stage Dementia

Late Stage Dementia

Late-Stage Dementia: severe cognitive impairment and declining function (inability to recognise loved ones, unable to ambulate independently, incontinence of urine or faeces)


Expert consensus is that these practices are recommended in the care of people with dementia

Treatment Goals

An important treatment goal for people living with dementia is to simplify the medication regimen.

Health professionals and the person living with dementia should discuss and document:

* likely prognosis

* writing an advance care directive to indicate their wishes for treatment in specific future scenarios

Health professionals and the carer or family of the person living with dementia should discuss and document:

* treatment goals

* likely prognosis

* document wishes for treatment in specific future scenarios

Medication Side Effects

People living with dementia are:

* at higher risk of side effects than cognitively-intact people

* often unable to recognise side effects from their medications

* often unable to report side effects from their medications

Principles of medication use

When prescribing for people living with dementia, health professionals should:

* provide a current medication list that includes indications, administration instructions, and planned dates for review

* regularly monitor for actual benefit of each medication

* regularly monitor for actual side effects

* start new medications at the lowest therapeutic dose

* review doses frequently to see if a lower dose would be adequate

* change only one medication at a time

* assess impact of dementia on activities of daily living

Medication reviews

When reviewing medications use for people living with dementia, health professionals should check that each medication is:

* underpinned by a current, valid indication

* effective for that individual

* consistent with individual’s care goals

* documented with a time frame to review

A medication review should be triggered by:

* a significant event (e.g. cardiovascular event, fall, fracture, hospital admission, residential care facility admission)

* increasing frailty

* resistance to taking medications

* belief taking medications is a burden

* writing a new prescription for the medication

* decline in cognitive function

* decline in ability to manage activities of daily living

* regular use of five or more medications

Preventative medication

When prescribing medications intended to modify the risk of a future event for a person living with dementia, health professionals should consider:

* functionality as the most important factor

* the potential benefits weighed against the actual harm

* potential for side effects

* actual side effects

* the risks of polypharmacy

* the administration burden

* maximise quality of life rather than prolong survival

* use less stringent targets for blood glucose

* only use diuretics for symptomatic management of heart failure

* cease antihypertensive agents

* cease lipid-lowering medications

* cease medications to manage osteoporosis

* cease anti-platelet, anti-coagulants and anti-thrombotic agents

* cease all medications that do not also provide tangible symptom relief

* cease medications that have a longer potential time to benefit than the person’s likely prognosis

Symptom management

* trialled for withdrawal every three to six months if the symptoms are stable

* reviewed regularly for efficacy

* reviewed regularly for side effects

* review doses frequently to see if symptoms can be adequately

* maintained on a lower dose

* maximised to alleviate distress

Psycho-active medications

* use non-pharmacological strategies in preference to medications

* benzodiazepines should not generally be used, but

* short acting benzodiazepines can be useful for managing acute agitation provided use is monitored

* antipsychotics can be useful when prescribed at a low dose for a limited period to alleviate distressing neuropsychiatric symptoms

* antipsychotics should be considered if distressing behavioural

* symptoms are not responsive to other management strategies

* tricyclic antidepressants have a limited role, but

* tricyclic antidepressants may be useful in managing refractory neuropathic pain

Medications to modify dementia progression

* stop dementia treatments in late stage dementia (i.e. memantine, anticholinesterases)

* maximise cognitive function by reducing exposure to medications with sedative and anticholinergic properties


Expert consensus is that these practices are NOT recommended in the care of people with dementia

Symptom Management

for people living with dementia, regular medications intended only to provide symptom relief should be continued indefinitely in people who are unable to reliably report symptom recurrence

Psycho-active medications

* for managing behavioural and psychological symptoms of dementia, antipsychotics are never appropriate for behavioural management

* for people living with dementia, long acting benzodiazepines can be useful, provided the risks are weighed against the benefits

DEFINITIONS

Dementia

A clinical syndrome characterized by a chronic progressive decline in neurocognitive function, specifically affecting memory, cognition, language, behaviour, emotional control, and social functioning beyond the expected effects of physiological aging and not attributable to an intercurrent illness.

The specific signs and symptoms of dementia and the rate of progression vary accordingly to the aetiology and individual. One or more aetiology may be present at the same time; the most common forms of dementia are Alzheimer’s, vascular, Lewy body, and fronto-temporal dementia.

Symptom relief

Symptom relief is defined as medication prescribed to control active disease, maintain quality of life, and relieve discomfort/distress from comorbidities. It is based on current, active symptoms rather than historical or documented symptoms.

Preventative medication

Preventative medication is defined as medication to prevent a future serious event or delay the progression of a comorbidity.

Early Stage Dementia

Mild cognitive impairment with a preserved ability to self-care and undertake activities of daily living.

Mid Stage Dementia

Moderate cognitive impairment with physical function often preserved. People with mid-stage dementia may be living with support in the community or a low care residential aged care setting.

Late Stage Dementia

Severe cognitive impairment and declining function (inability to recognise loved ones, unable to ambulate independently, incontinence of urine or faeces).

Downloads

MATCH-D Criteria

  • MATCH-D in black and white – five pages – A4
  • MATCH-D in colour – five pages – A4
  • MATCH-D as a booklet colour – twelve page – A5

Checklists – Health professional use

PDF – Early stage, Mid stage, Late stage

DOCX – Early stage, Mid stage, Late stage

Why do we need the MATCH-D criteria?

Most people living with dementia have at least one other health condition. They often use medications to manage their other health conditions, but we don’t have much information to guide us on whether this is appropriate. Information to help us optimise medication use for older adults generally are helpful, but people living with dementia have specific needs as they are living with a progressive life-limiting condition.

About MATCH-D

The MATCH-D statements are in the broad themes of preventative medication, symptom management, disease progression, psycho-active medication, treatment goals, principles of medication use, side effects, and medication reviews.

Research Team

The MATCH-D criteria was developed by an interprofessional team of Australian researchers. Dr Amy Theresa Page, Dr Kathleen Potter, Professor Rhonda Clifford and Associate Professor Christopher Etherton-Beer at the University of Western Australia and Professor Andrew McLachlan at the University of Sydney.

Research Centre

WA Centre for Health and Ageing, University of Western Australia Centre for Optimisation of Medicines, University of Western Australia

Published Research

The development of the MATCH-D is published research is available in the Internal Medicine Journal.

The enablers and barriers are published in the BMJ Open.

 

The systematic review that informed the MATCH-D criteria and the protocol are also published.

 

The publications are Open Access, meaning they are available free of charge.

Download files

MATCH-D Criteria

  • MATCH-D in black and white – five pages – A4
  • MATCH-D in colour – five pages – A4
  • MATCH-D as a booklet colour – twelve page – A5

Checklists – Health professional use

PDF – Early stage, Mid stage, Late stage

DOCX – Early stage, Mid stage, Late stage

Page A, Potter K, Clifford R, McLachlan AJ, Etherton-Beer C. Medication Appropriateness Tool for Comorbid Health conditions in Dementia (MATCH-D): Consensus recommendations from a multidisciplinary expert panel. Internal Medicine Journal. 2016 In Press